Clear Street raised the firm’s price target on Delcath Systems (DCTH) to $29 from $28 and keeps a Buy rating on the shares after the company announced preliminary Q4 results. Hepzato is now a “steady contributor for Delcath, with quarter-to-quarter variability more predictable, growth still available, and cash flow to fund expansion indications, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems reports preliminary Q4 revenue $20.7M, consensus $19.99M
- Delcath Systems publishes results from subgroup analyses of FOCUS study
- Delcath Systems announces publication of CHEMOSAT study
- Closing Bell Movers: Elastic down 12% despite beat and raise
- Delcath Systems Announces $25M Share Buyback Plan